Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
Poster Session A
Title: Update on FORTITUDE-ALS: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis
Presentation Time: 5:45 –
Poster Moderated: 6:00 –
Poster Number: CLT-24
Theme: CLT9, Clinical trials and clinical design
Poster Presenter:
Title: Correlation of SVC Measured at
Presentation Time: 5:45 –
Poster Moderated: 6:00 –
Poster Number: CLT-04
Theme: CLT9, Clinical trials and clinical design
Poster Presenter:
Title: VITALITY-ALS: Changes from Baseline in Percent Predicted SVC and ALSFRS-R Among Patients with Time from ALS Diagnosis < 6.1 Months
Presentation Time: 5:45 –
Poster Moderated: 6:00 –
Poster Number: CLT-22
Theme: CLT9, Clinical trials and clinical design
Poster Presenter:
Title: Non-Invasive Ventilation use in Patients Enrolled in VITALITY-ALS
Presentation Time: 5:45 –
Poster Moderated: 6:00 –
Poster Number: CLT-05
Theme: CLT9, Clinical trials and clinical design
Poster Presenter:
Poster Session B
Title: Updated Results from a
Presentation Time: 5:45 –
Poster Moderated: 6:00 –
Poster Number: EPI-29
Theme: 5, Epidemiology and Informatics
Poster Presenter:
About
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. ("Amgen") to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is also collaborating with Amgen to develop AMG 594, a first-in-class cardiac troponin activator, discovered under the companies' joint research program. Further development of AMG 594 is subject to the collaboration agreement between Amgen and Cytokinetics. Cytokinetics is collaborating with Astellas Pharma Inc. ("Astellas") to develop reldesemtiv, a fast skeletal muscle troponin activator (FSTA). Reldesemtiv has been granted orphan drug designation by the FDA for the potential treatment of spinal muscular atrophy. Reldesemtiv was the subject of a positive Phase 2 clinical study in patients with spinal muscular atrophy which showed increases in measures of endurance and stamina consistent with the mechanism of action. Reldesemtiv is currently the subject of a Phase 2 clinical trial in patients with amyotrophic lateral sclerosis. Cytokinetics is also advancing CK-601, a next-generation FSTA into IND-enabling studies under the collaboration with Astellas. Astellas holds an exclusive worldwide license to develop and commercialize reldesemtiv. Licenses held by Amgen and Astellas are subject to specified co-development and co-commercialization rights of Cytokinetics. Cytokinetics recently filed an IND for CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations. Cytokinetics continues its 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").
Contact:
Vice President, Corporate Communications, Investor Relations
(415) 290-7757
Source: Cytokinetics, Incorporated